{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:27:59Z","timestamp":1780478879843,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research","doi-asserted-by":"crossref","award":["200101MSH-87845-60447"],"award-info":[{"award-number":["200101MSH-87845-60447"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.jcjo.2012.03.026","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T16:19:40Z","timestamp":1380644380000},"page":"275-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections"],"prefix":"10.1016","volume":"47","author":[{"given":"Sanjay","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davin","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Abouammoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hollands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Brissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2012.03.026_bib1","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2012.03.026_bib2","series-title":"Canadian Ophthalmology Society Annual Conference and Exhibition","article-title":"Outbreak of acute intraocular inflammation after bevacizumab intravitreal injection: An epidemiological investigation","year":"2009"},{"key":"10.1016\/j.jcjo.2012.03.026_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/bjo.2008.138479","article-title":"Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)","volume":"93","author":"Georgopoulos","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.03.026_bib4","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ophtha.2008.05.007","article-title":"Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration","volume":"115","author":"Wickremasinghe","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2012.03.026_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/IAE.0b013e3181bd2d51","article-title":"Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch","volume":"30","author":"Yamashiro","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2012.03.026_bib6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ophtha.2009.07.041","article-title":"Severe intraocular inflammation after intravitreal injection of bevacizumab","volume":"117","author":"Sato","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2012.03.026_bib7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/IAE.0b013e3181baf691","article-title":"Toxic vitritis outbreak after intravitreal injection","volume":"30","author":"Ness","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2012.03.026_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3129\/i10-013","article-title":"Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: A retrospective cohort study","volume":"45","author":"Johnson","year":"2010","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.03.026_bib9","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1111\/j.1755-3768.2010.02054.x","article-title":"Acute intraocular inflammation following intravitreal injection of bevacizumab: A large cluster of cases","volume":"89","author":"Fielden","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.03.026_bib10","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/IAE.0b013e3181dc04da","article-title":"Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection","volume":"30","author":"Chong","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2012.03.026_bib11","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jcjo.2012.03.026_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.03.026_bib13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/IAE.0b013e3181b20eed","article-title":"Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration","volume":"29","author":"Chang","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2012.03.026_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/IAE.0b013e31819a5f98","article-title":"Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: Our experience after 2,000 injections","volume":"29","author":"Ladas","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2012.03.026_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000227783","article-title":"Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration","volume":"223","author":"Landa","year":"2009","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jcjo.2012.03.026_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ophtha.2009.07.023","article-title":"Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: A multicenter, retrospective study","volume":"117","author":"Fong","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2012.03.026_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10792-009-9318-7","article-title":"Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration","volume":"30","author":"Gamulescu","year":"2010","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.03.026_bib18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ajo.2009.10.010","article-title":"Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab: A randomized controlled trial","volume":"149","author":"Gharbiya","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.03.026_bib19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2009.07.009","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial","volume":"148","author":"Subramanian","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.03.026_bib20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/IAE.0b013e3181cd47ed","article-title":"Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor","volume":"30","author":"Mezad-Koursh","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2012.03.026_bib21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00417-007-0754-7","article-title":"Intraocular inflammation following intravitreal injection of bevacizumab","volume":"246","author":"Bakri","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.03.026_bib22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2012.03.026_bib23","series-title":"Canadian Ophthalmology Society Annual Conference and Exhibition","article-title":"Aucte intraocular inflammation following intravitreal injection of bevacizumab-a cluster of cases","year":"2009"},{"key":"10.1016\/j.jcjo.2012.03.026_bib24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","article-title":"Structure-immunogenicity relationships of therapeutic proteins","volume":"21","author":"Hermeling","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jcjo.2012.03.026_bib25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/cvr\/28.8.1176","article-title":"Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: Implications for coronary angiogenesis","volume":"28","author":"Banai","year":"1994","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jcjo.2012.03.026_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1050-1738(01)00149-9","article-title":"Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia","volume":"12","author":"Zhang","year":"2002","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jcjo.2012.03.026_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/359843a0","article-title":"Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis","volume":"359","author":"Shweiki","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jcjo.2012.03.026_bib28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jcjo.2012.03.026_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI9369","article-title":"VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain","volume":"106","author":"Zhang","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcjo.2012.03.026_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jnr.21091","article-title":"VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion","volume":"85","author":"Wang","year":"2007","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.jcjo.2012.03.026_bib31","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1172\/JCI200317977","article-title":"VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia","volume":"111","author":"Sun","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcjo.2012.03.026_bib32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jnr.21169","article-title":"VEGF-overexpressing transgenic mice show enhanced post-ischemic neurogenesis and neuromigration","volume":"85","author":"Wang","year":"2007","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.jcjo.2012.03.026_bib33","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2012.03.026_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2012.03.026_bib35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-145-2-200607180-00007","article-title":"Age-related macular degeneration and risk for stroke","volume":"145","author":"Wong","year":"2006","journal-title":"Ann Intern Med"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418212001433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418212001433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:02:03Z","timestamp":1757793723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418212001433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0008418212001433"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2012.03.026","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2012.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}